Citadel Advisors »

Inhibikase Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $116k 72k 1.62
2024-06-30 $50k 38k 1.31

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
Perceptive Advisors
Commodore Capital
ADAR1 Capital Management
Vanguard Group
BlackRock
Blackstone Group
Nantahala Capital Management
Geode Capital Management
Stonepine Capital Management
State Street Corporation
Northern Trust
William Blair $ Company

View all funds holding Inhibikase Therapeutics